The Therapeutic Role of rTMS in Children with ADHD a Pilot Study

Phase 2

• Conditions: Mental and Behavioural Disorders

• Registration Number: PACTR202110558451583
• Lead Sponsor: FACULTY OF MEDCINE AIN SHAMS UNIVERSITY

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-25
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients diagnosed with ADHD according to DSM IV
Age ranges 7-12 years old
All patients will be on the same type of medications throughout the duration of the study (Atomoxetine 1.2 mg/kg/day)

Exclusion Criteria

Factors that might increase the risk of seizure with TMS such as a history of a seizure disorder, febrile seizures during childhood, known brain lesions, or a history of major head trauma involving loss of consciousness for more than 5 minutes.

Specific contraindications to magnetic stimulation such as any metallic object implanted in the skull (with the exception of oral dental devices), an implanted medication pump or cochlear implant, implanted intra-cardiac lines or pacemaker.

Comorbid diagnosis of autism spectrum disorder, bipolar disorder, obsessive-compulsive disorder, conduct disorder, Tourette disorder or other tic disorders, schizophrenia, schizoaffective disorder, or any other psychotic disorder.

Any other neurological disorders.

Study & Design

• Study Type: Interventional
• Study Design: Not specified